Metafoodx | $9,400,000 | (May 16, 2025)
Ascendx | $110,000,000 | (May 16, 2025)
Algoma | $2,300,000 | (May 16, 2025)
Certified by Founder
Lodge
Bryleos
start up
United States
- Johnson City, Tennessee
- 14/06/2023
- Seed
- $5,000,000
Early clinical stage therapeutics company developing BNAD101, a patent-pending oral composition of NAD+ clinically proven to increase intracellular NAD+. BNAD101 is a potential high-value medicine to treat challenging and costly neurological disorders.
In 2022, the Company completed its double-blind, placebo-controlled proof of concept study at the Institute of Systems Biology. The study of 60 healthy adults demonstrated BNAD101 had a 52% increase in intracellular NAD levels against placebo within just 5 days, effectively validating the potential of BNAD101 in treating not only chronic neurological conditions but conditions were swift response is critical.
Bryleos: More Life While Living
- Industry Biotechnology Research
- Website https://bryleos.com/
- LinkedIn https://www.linkedin.com/company/bryleos/
Plakar | $3,000,000 | (May 16, 2025)
Solestial, Inc. | $17,000,000 | (May 16, 2025)
Adyton PBC | $11,000,000 | (May 16, 2025)
Sproutr | Undisclosed Amount | (May 16, 2025)
Voltra | $1,800,000 | (May 16, 2025)
IMPRINT(US) | $15,000,000 | (May 16, 2025)
Sprinter Health | $55,000,000 | (May 16, 2025)
CarbonSix | $4,000,000 | (May 16, 2025)
Zeno Power | $50,000,000 | (May 16, 2025)